Johannes F. Fahrmann, Ph.D.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Assistant Professor, Clinical Cancer Prevention - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2015-2017 | Postdoctoral Fellow, Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2013-2015 | Postdoctoral Fellow, NIH West Coast Metabolomics Center, University of California, Davis, California |
Experience & Service
Extramural Institutional Committee Activities
Review Panel, NIH study section, The University of Texas MD Anderson Cancer Center, 2026 - Present
Reviewer, Military Medical Research, The University of Texas MD Anderson Cancer Center, 2026 - Present
Reviewer, CDMRP BM-2, The University of Texas MD Anderson Cancer Center, 2026 - Present
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2026
T32 Training Grant Steering Committee Member, NCI Training Program in Translational Genomics and Precision Medicine in Cancer, The University of Texas MD Anderson Cancer Center, 2025 - Present
Reviewer, CPRTP - Gordon Colorectal Postdoctoral Fellowship Research, The University of Texas MD Anderson Cancer Center, 2025
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2025
Representative, Faculty Senate Representative for Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, 2024 - 2027
Representative, Medical Technology Innovation Council, The University of Texas MD Anderson Cancer Center, 2024 - 2025
Review Panel, Distinguished Faculty Mentor Award, The University of Texas MD Anderson Cancer Center, 2024
Awards Reviewer, FY23 Endowed Fellowship Research Excellence, The University of Texas MD Anderson Cancer Center, 2024
Review Board, DCPPS Employee Recognition Awards, The University of Texas MD Anderson Cancer Center, 2024
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2024
Award Judge, Distinguished Mentor, The University of Texas MD Anderson Cancer Center, 2024
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2023
Abstract Reviewer, Trainee Research Day, The University of Texas MD Anderson Cancer Center, 2023
Grant Reviewer, Endowed Fellowship Pilot, The University of Texas MD Anderson Cancer Center, 2023
Postdoctoral Fellowship Proposal Reviewer, Cancer Prevention Research in Texas (CPRIT), The University of Texas MD Anderson Cancer Center, 2022
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2022
Grant Reviewer, Endowed Fellowship Pilot, The University of Texas MD Anderson Cancer Center, 2022
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2021
Evaluation of Fellowship Proposal, Cancer Prevention Research Training Program (CPRTP), The University of Texas MD Anderson Cancer Center, 2020
Editorial Activities
Editor, Journal of Ovarian Research
Guest Editor, Special issue on Molecular Diagnostics and Therapeutics for Frontiers in Molecular Biosciences
Guest Editor, Special issue on Unmasking metabolic dependencies for anti-cancer treatment for Frontiers of Oncology
Guest Editor, Special issue on Cancer Proteometabolomics for Cancers
Guest Editor, Special issue on Cancer Genetics and Oncogenomics for Frontiers in Genetics
Honors & Awards
| 2023 - Present | Early Detention Research Network Early Career Investigator |
| 2020 - Present | MD Anderson SPORE in Ovarian Cancer Career Enhancement Program, The University of Texas MD Anderson Cancer Center - Houston, TX |
| 2019 - 2021 | McKee Early Career Investigator in Pancreatic Cancer Research |
| 2019 | Spotlight Award for Outstanding Work, Department of Clinical Cancer Prevention at The University of Texas MD Anderson Cancer Center |
| 2017 - 2024 | Mentored Junior Faculty Fellowship in Cancer Prevention Research, Duncan Family Institute for Cancer Prevention and Risk Assessment, Division of Cancer Prevention & Population Sciences. The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2012 | Best Research Performance for the Academic Year, National Travel Award |
| 2011 | Honorary Member of Marshall University Award, Marshall University |
| 2010 - 2011 | Grand Club Top Fundraiser- Relay-For-Life, Marshall University |
| 2008 | NASA Scholarship Recipient, NASA |
| 2004 - 2008 | Promise Scholarship Recipient, Promise Award |
| 2004 - 2006 | Presidential Scholarship Recipient |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Multi-Cancer Early Detection and Risk Assessment: Challenges and Paths Forward. Invited. 45th EDRN Steering Committee. Houston, Texas, US.
- 2025. Biomarkers for risk prediction of pancreatic cancer from new-onset diabetes, US.
- 2024. Blood-based biomarkers for risk prediction of pancreatic cancer. Houston, Texas, US.
- 2023. Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration. Houston, Texas, US.
- 2017. Kynureninase is Predictive of Poor Survival in Lung Adenocarcinoma and its Immunosuppressive Effects are Mediated through an Altered Metabolic Phenotype. 3rd. Conference. Annual Immuno-Oncology Young Investigator’s Forum. Houston, TX, US.
- 2016. Applied Metabolomics for Risk Assessment of Cancer. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2021. Blood-based biomarkers for risk assessment and early detection of pancreatic cancer. Invited. Department of Medical Oncology and Therapeutic Research, CA, US.
- 2013. he Imbalance that Persists: Application of Omega-3 Fatty Acids as Therapeutic Options for Cancers. Conference. Marshall University School of Medicine. Huntington, WV, US.
- 2013. Omega-3 Fatty Acids Are Potential Chemo-sensitizing Agents for the Treatment of B-Cell Chronic Lymphocytic Leukemia. Conference. Marshall University School of Medicine. Huntington, WV, US.
National Presentations
- 2020. A blood-based biomarker panel for early stage pancreatic cancer. Conference. SU2C-Lustgarten Pancreatic Interception Team Meeting, US.
- 2020. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Conference. National Cancer Institute Early Detection Research Network, US.
- 2020. Validation of a MYC-driven polyamine signature in combination with a protein panel for the early detection of SCLC using PLCO samples. Conference. NIH, US.
- 2019. A Plasma-derived Protein-Metabolite Multiplexed Panel for Early Stage Pancreatic Cancer. Conference. NCI Division of Cancer Prevention. Bethesda, MD, US.
- 2019. A Plasma-derived Protein-Metabolite Multiplexed Panel for Early Stage Pancreatic Cancer. Conference. Symposia on Molecular and Cellular Biology. Keystone, CO, US.
- 2019. A Plasma-derived Protein-Metabolite Multiplexed Panel for Early Stage Pancreatic Cancer. Conference. Pancreatic Cancer Collective Symposium. Philadelphia, PA, US.
- 2018. Plasma-derived Metabolite and Protein Biomarker Panels Have Additive Performance for Early Stage Pancreatic Cancer. Conference. Metabolomics Society. Seattle, WA, US.
- 2018. JAK/STAT3-Regulated Fatty Acid ß-Oxidation is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Conference. BioLegend, Inc., Cancer Research UK, Cell Research, EMD Serono Research and Development Institute Inc., Incyte Corporation and Merck & Co., Inc. Snowbird, UT, US.
- 2017. Metabolomics Identifies a Caveolin-1-associated Plasma Glycosphingolipid and Sphingomyelin Signature that Differentiates Aggressive from Indolent Prostate Cancer in an Active Surveillance Cohort. Conference. AACR. Washington, DC, US.
- 2012. Inhibition of Nuclear Factor Kappa B activation in Early Stage Chronic Lymphocytic Leukemia by Omega 3 Fatty Acids. Conference. American Society for Pharmacology and Experimental Therapeutics (ASPET). San Diego, CA, US.
International Presentations
- 2017. Early-Career Metabolomics Network Hosted Workshops. Invited. Metabolomics Society 13th Annual Conference. Brisbane, AU.
Grant & Contract Support
| Date: | 2025 - 2026 |
| Title: | Molecular Classification of DCIS: Implications for Clinical Management |
| Funding Source: | Breast Cancer Research Foundation |
| Role: | Co-I |
| ID: | FP00022691_Rev1 |
| Date: | 2025 - 2030 |
| Title: | Validation of blood-based biomarkers for risk assessment of lung cancer among individuals with no smoking history in the PLCO Cohort |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | U01CA295902 |
| Date: | 2025 - 2026 |
| Title: | Pancreatic Moon Shot, Priority Project 1 |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-I |
| ID: | N/A |
| Date: | 2025 - 2029 |
| Title: | Bile acids as a mediator of the diet-microbiome-immune axis |
| Funding Source: | V Foundation |
| Role: | Co-I |
| ID: | FP00025623 |
| Date: | 2025 - 2030 |
| Title: | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA299972 |
| Date: | 2025 - 2029 |
| Title: | Randomized Clinical Trial Evaluating Fecal Microbiota Transplant in Chimeric Antigen Receptor Therapy for Reversing Antimicrobial-Associated Dysbiosis |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP250131 |
| Date: | 2025 - 2029 |
| Title: | Blood based biomarkers to guide clinical decision making with indeterminate pulmonary nodules |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP250269 |
| Date: | 2024 - 2029 |
| Title: | Proteotoxic Metabolites in Genome Instability and Disease |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01CA295874 |
| Date: | 2024 - 2029 |
| Title: | Pancreatic Cancer North America |
| Funding Source: | Pancreatic Cancer North America (PCNA) |
| Role: | PI |
| ID: | N/A |
| Date: | 2023 - 2028 |
| Title: | Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer |
| Funding Source: | NIH |
| Role: | Co-I |
| ID: | R01 CA281727 |
| Date: | 2023 - 2028 |
| Title: | Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer |
| Funding Source: | NCI |
| Role: | PI |
| ID: | U01CA282216 |
| Date: | 2023 - 2028 |
| Title: | Repurposing glucosylceramide synthase to promote mitochondrial lethality and potentiate an anti-tumor immune response in triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R37CA269611 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01CA200468 |
Selected Publications
Peer-Reviewed Articles
- Ben-Ami R, Wang QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJ, Jänne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut 73(4):639-648, 2023. e-Pub 2023. PMID: 38123998.
- Zhang X, Irajizad E, Hoffman KL, Fahrmann JF, Li F, Seo YD, Browman GJ, Dennison JB, Vykoukal J, Luna PN, Siu W, Wu R, Murage E, Ajami NJ, McQuade JL, Wargo JA, Long JP, Do KA, Lampe JW, Basen-Engquist KM, Okhuysen PC, Kopetz S, Hanash SM, Petrosino JF, Scheet P, Daniel CR. Modulating a prebiotic food source influences inflammation and immune-regulating gut microbes and metabolites: insights from the BE GONE trial. EBioMedicine 98:104873, 2023. e-Pub 2023. PMID: 38040541.
- Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression. Clin Cancer Res 29(21):4464-4478, 2023. e-Pub 2023. PMID: 37581614.
- Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E. Exercise Training Reduces the Inflammatory Response and Promotes Intestinal Mucosa-Associated Immunity in Lynch Syndrome. Clin Cancer Res 29(21):4361-4372, 2023. e-Pub 2023. PMID: 37724990.
- Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Wu R, Dennison JB, Peterson CB, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Jha S, Rivero JD, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM, Katayama H. Blood-based Proteomic Signatures Associated With MEN1-related Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab 108(12):3260-3271, 2023. e-Pub 2023. PMID: 37307230.
- Irajizad E, Fahrmann JF, Marsh T, Vykoukal J, Dennison JB, Long JP, Do KA, Feng Z, Hanash S, Ostrin EJ. Mortality Benefit of a Blood-Based Biomarker Panel for Lung Cancer on the Basis of the Prostate, Lung, Colorectal, and Ovarian Cohort. J Clin Oncol 41(27):4360-4368, 2023. e-Pub 2023. PMID: 37379494.
- Mukherjee A, Bezwada D, Greco F, Zandbergen M, Shen T, Chiang CY, Tasdemir M, Fahrmann J, Grapov D, La Frano MR, Vu HS, Faubert B, Newman JW, McDonnell LA, Nezi L, Fiehn O, DeBerardinis RJ, Lengyel E. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab 5(9):1563-1577, 2023. e-Pub 2023. PMID: 37653041.
- Irajizad E, Kenney A, Tang T, Vykoukal J, Wu R, Murage E, Dennison JB, Sans M, Long JP, Loftus M, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger JM, Maitra A, Do KA, Yu B, Wolpin BM, Hanash S, Fahrmann JF. A blood-based metabolomic signature predictive of risk for pancreatic cancer. Cell Rep Med 4(9):101194, 2023. e-Pub 2023. PMID: 37729870.
- Sans M, Makino Y, Min J, Rajapakshe KI, Yip-Schneider M, Schmidt CM, Hurd MW, Burks JK, Gomez JA, Thege FI, Fahrmann JF, Wolff RA, Kim MP, Guerrero PA, Maitra A. Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential. Cancer Discov 13(8):1844-1861, 2023. e-Pub 2023. PMID: 37285225.
- Kraler S, Wenzl FA, Vykoukal J, Fahrmann JF, Shen MY, Chen DY, Chang KC, Chang CK, von Eckardstein A, Räber L, Mach F, Nanchen D, Matter CM, Liberale L, Camici GG, Akhmedov A, Chen CH, Lüscher TF, investigators S. Low-density lipoprotein electronegativity and risk of death after acute coronary syndromes: A case-cohort analysis. Atherosclerosis 376:43-52, 2023. e-Pub 2023. PMID: 37285778.
- Irajizad E, Han CY, Celestino J, Wu R, Murage E, Spencer R, Dennison JB, Vykoukal J, Long JP, Do KA, Drescher C, Lu K, Lu Z, Bast RC, Hanash S, Fahrmann JF. A blood-based metabolite panel for distinguishing ovarian cancer from benign pelvic masses. Clin Cancer Res 28(21):4669-4676, 2022. e-Pub 2022. PMID: 36037307.
- Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, Yuan Y, Ann D, Hanash S, Yu H. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep 39(13):111044, 2022. e-Pub 2022. PMID: 35767954.
- Li YJ, Fahrmann JF, Aftabizadeh M, Zhao Q, Tripathi SC, Zhang C, Yuan Y, Ann D, Hanash S, Yu H. Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. Cell Rep 39(9):110870, 2022. e-Pub 2022. PMID: 35649368.
- Fahrmann JF, Marsh T, Irajizad E, Patel N, Murage E, Vykoukal J, Dennison JB, Do KA, Ostrin E, Spitz MR, Lam S, Shete S, Meza R, Tammemägi MC, Feng Z, Hanash SM. Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment. J Clin Oncol 40(8):JCO2101460, 2022. e-Pub 2022. PMID: 34995129.
- Tanaka I, Dayde D, Tai MC, Mori H, Solis LM, Tripathi SC, Fahrmann JF, Unver N, Parhy G, Jain R, Parra ER, Murakami Y, Aguilar-Bonavides C, Mino B, Celiktas M, Dhillon D, Casabar JP, Nakatochi M, Stingo F, Baladandayuthapani V, Wang H, Katayama H, Dennison JB, Lorenzi PL, Do KA, Fujimoto J, Behrens C, Ostrin EJ, Rodriguez-Canales J, Hase T, Fukui T, Kajino T, Kato S, Yatabe Y, Hosoda W, Kawaguchi K, Yokoi K, Chen-Yoshikawa TF, Hasegawa Y, Gazdar AF, Wistuba II, Hanash S, Taguchi A. SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas. J Natl Cancer Inst 114(2):290-301, 2022. e-Pub 2022. PMID: 34524427.
- Chen Y, Capello M, Rios Perez MV, Vykoukal JV, Roife D, Kang Y, Prakash LR, Katayama H, Irajizad E, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Do KA, Fiehn O, Maitra A, Wang H, Chiao PJ, Katz MHG, Fleming JB, Hanash SM, Fahrmann JF. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop. Mol Metab 56:101426, 2022. e-Pub 2022. PMID: 34971802.
- Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab 106(12):e4969-e4980, 2021. e-Pub 2021. PMID: 34318891.
- Katayama H, Kobayashi M, Irajizad E, Sevillarno A, Patel N, Mao X, Rusling L, Vykoukal J, Cai Y, Hsiao F, Yu CY, Long J, Liu J, Esteva F, Fahrmann JF, Hanash S. Protein citrullination as a source of cancer neoantigens. J Immunother Cancer 9(6), 2021. e-Pub 2021. PMID: 34112737.
- Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP, Do KA, Zhang J, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger J, Yip-Schneider MT, Maitra A, Wolpin BM, Hanash S. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology 160(4):1373-1383.e6, 2021. e-Pub 2021. PMID: 33333055.
- Ostrin EJ, Bantis LE, Wilson DO, Patel N, Wang R, Kundnani D, Adams-Haduch J, Dennison JB, Fahrmann JF, Chiu HT, Gazdar A, Feng Z, Yuan JM, Hanash SM. Contribution of a blood-based protein biomarker panel to the classification of indeterminate pulmonary nodules. J Thorac Oncol 16(2):228-236, 2021. e-Pub 2021. PMID: 33137463.
- Capello M, Fahrmann JF, Rios Perez MV, Vykoukal JV, Irajizad E, Tripathi SC, Roife D, Bantis LE, Kang Y, Kundnani DL, Xu H, Prakash LR, Long JP, Katayama H, Fleury A, Ferri-Borgogno S, Baluya DL, Dennison JB, Aguilar-Bonavides C, Casabar JP, Celiktas M, Do KA, Fiehn O, Maitra A, Wang H, Feng Z, Chiao PJ, Katz MH, Fleming JB, Hanash SM. CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes. JCO Precis Oncol 4:426-436, 2020. e-Pub 2020. PMID: 35050739.
- Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, Park S, Yang G, Creighton CJ, Fleury A, Mayo J, Paulucci-Holthauzen A, Dennison JB, Murage E, Peterson CB, Davis JW, Kim J, Hanash S, Thompson TC. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun 11(1):4279, 2020. e-Pub 2020. PMID: 32855410.
- Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, Wang P, Yu CY, Capello M, Creighton CJ, Do KA, Long JP, Irajizad E, Peterson C, Katayama H, Disis ML, Arun B, Hanash S. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple negative breast cancer. J Natl Cancer Inst 112(6):607-616, 2020. e-Pub 2020. PMID: 31503278.
- Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res 80(8):1748-1761, 2020. e-Pub 2020. PMID: 32054768.
- Taguchi A, Fahrmann JF, Hanash SM. A Promising CPS1 Inhibitor Keeping Ammonia from Fueling Cancer. Cell Chem Biol 27(3):253-254, 2020. e-Pub 2020. PMID: 32200911.
- Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, Murage E, Vykoukal J, Kundnani DL, Foretova L, Fabianova E, Holcatova I, Janout V, Feng Z, Yip-Schneider M, Zhang J, Brand R, Taguchi A, Maitra A, Brennan P, Max Schmidt C, Hanash S. A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. J Natl Cancer Inst 111(4):372-379, 2019. e-Pub 2019. PMID: 30137376.
- Wang T, Fahrmann JF, Lee H, Li YJ, Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, Somlo G, Jandial R, Ann D, Hanash S, Jove R, Yu H. JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27(1):136-150.e5, 2018. e-Pub 2018. PMID: 29249690.
- Tripathi SC, Fahrmann JF, Celiktas M, Aguilar M, Marini KD, Jolly MK, Katayama H, Wang H, Murage EN, Dennison JB, Watkins DN, Levine H, Ostrin EJ, Taguchi A, Hanash SM. MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway. Cancer Res 77(16):4414-4425, 2017. e-Pub 2017. PMID: 28646020.
- DeFelice BC, Mehta SS, Samra S, Cajka T, Wancewicz B, Fahrmann JF, Fiehn O. Mass Spectral Feature List Optimizer (MS-FLO): A Tool To Minimize False Positive Peak Reports in Untargeted Liquid Chromatography-Mass Spectroscopy (LC-MS) Data Processing. Anal Chem 89(6):3250-3255, 2017. e-Pub 2017. PMID: 28225594.
- Çeliktas M, Tanaka I, Tripathi SC, Fahrmann JF, Aguilar-Bonavides C, Villalobos P, Delgado O, Dhillon D, Dennison JB, Ostrin EJ, Wang H, Behrens C, Do KA, Gazdar AF, Hanash SM, Taguchi A. Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. J Natl Cancer Inst 109(3):1-9, 2017. e-Pub 2017. PMID: 28376202.
- Lam WY, Becker AM, Kennerly KM, Wong R, Curtis JD, Llufrio EM, McCommis KS, Fahrmann J, Pizzato HA, Nunley RM, Lee J, Wolfgang MJ, Patti GJ, Finck BN, Pearce EL, Bhattacharya D. Mitochondrial Pyruvate Import Promotes Long-Term Survival of Antibody-Secreting Plasma Cells. Immunity 45(1):60-73, 2016. e-Pub 2016. PMID: 27396958.
- Borrego SL, Fahrmann J, Datta R, Stringari C, Grapov D, Zeller M, Chen Y, Wang P, Baldi P, Gratton E, Fiehn O, Kaiser P. Metabolic changes associated with methionine stress sensitivity in MDA-MB-468 breast cancer cells. Cancer Metab 4:9, 2016. e-Pub 2016. PMID: 27141305.
- Liesenfeld DB, Grapov D, Fahrmann JF, Salou M, Scherer D, Toth R, Habermann N, Böhm J, Schrotz-King P, Gigic B, Schneider M, Ulrich A, Herpel E, Schirmacher P, Fiehn O, Lampe JW, Ulrich CM. Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study. Am J Clin Nutr 102(2):433-43, 2015. e-Pub 2015. PMID: 26156741.
- Ray K, Fahrmann J, Mitchell B, Paul D, King H, Crain C, Cook C, Golovko M, Brose S, Golovko S, Santanam N. Oxidation-sensitive nociception involved in endometriosis-associated pain. Pain 156(3):528-39, 2015. e-Pub 2015. PMID: 25599233.
- Ma Y, Kind T, Vaniya A, Gennity I, Fahrmann JF, Fiehn O. An in silico MS/MS library for automatic annotation of novel FAHFA lipids. J Cheminform 7:53, 2015. e-Pub 2015. PMID: 26579213.
Review Articles
- Kobayashi M, Katayama H, Fahrmann JF, Hanash SM. Development of autoantibody signatures for common cancers. Semin Immunol 47:101388, 2020. e-Pub 2020. PMID: 31924500.
Editorials
- Vykoukal JV, Fahrmann JF, Thompson TC. Caveolin and lipid domains-close companions in managing cellular pathways. Cancer Metastasis Rev 39(2):341-342, 2020. PMID: 32417992.
- Kato T, Fahrmann JF, Hanash SM, Vykoukal J. Extracellular Vesicles Mediate B Cell Immune Response and Are a Potential Target for Cancer Therapy. Cells 9(6), 2020. PMID: 32580358.
Book Chapters
- Tripathi, SC, Fahrmann, JF, Amle, D. Targeting the Immuno-Oncology Metabolism in Cancer, 117-152, 2022.
- Fahrmann JF, Witte TR, Hardman WE. Cancer Therapy May be Improved if Diet Contains Omega 3 Fatty Acids. In: Cutting Edge Therapies for Cancer in the 21st Century. Bentham eBooks, Bentham Science Publishers Ltd, 387-424, 2014.
Patient Reviews
CV information above last modified September 15, 2026